Suzhou Teligene
China - SuzhouBiotechnology
Focus: Suzhou Teligene is a pre-revenue oncology-focused biotech founded in 2021, headquartered in Suzhou, China, specializing in small-molecule therapeutics for cancer treatment.
Profile data last refreshed 16h ago · AI intelligence enriched 1w ago
Open Jobs
0
About Suzhou Teligene
AI assessmentNot HiringNo open roles listed right now. Follow Suzhou Teligene to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
TL938 Capsules
Colorectal Cancer MetastaticClinical Trials (1)
NCT06589830TL938 and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer
Phase 2Help build intelligence for Suzhou Teligene
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.